DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/vznpzg/p53_signaling) has announced the addition of the "p53 Signaling Pathway in Cancer Drug Pipeline" report to their offering.

“p53 Signaling Pathway in Cancer Drug Pipeline”

p53 activation is induced by a number of stress signals, including DNA damage, oxidative stress and activated oncogenes. The p53 protein is employed as a transcriptional activator of p53-regulated genes. This results in three major outputs; cell cycle arrest, cellular senescence or apoptosis. Other p53-regulated gene functions communicate with adjacent cells, repair the damaged DNA or set up positive and negative feedback loops that enhance or attenuate the functions of the p53 protein and integrate these stress responses with other signal transduction pathways.

There are today 95 companies plus partners developing 85 p53 signaling pathway targeting drugs in 248 developmental projects in cancer. In addition, there are 2 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 55 drugs. P53 Signaling Pathway In Cancer Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 67 different targets. All included targets have been cross-referenced for the presence of mutations associated with human cancer. To date 65 out of the 65 studied drug targets so far have been recorded with somatic mutations. The software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information.

All drugs targets are further categorized on in the software application by 31 classifications of molecular function and with pathway referrals to BioCarta, KEGG, NCI-Nature and NetPath.

Reasons To Buy

- Show investors/board/management that you are right on top of drug development progress in your therapeutic area.

- Find competitors, collaborations partners, M&A candidates etc.

- Jump start competitive drug intelligence operations

- Excellent starting point for world wide benchmarking

- Compare portfolio and therapy focus with your peers

- Speed up pro-active in-/out licensing strategy work

- Fast and easy way of tracking drugs using search engines

For more information visit http://www.researchandmarkets.com/research/vznpzg/p53_signaling.

About Research and Markets

Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.